Dr Reddy's Laboratories is set to launch its generic semaglutide injection, Obeda, in India this March, as patent protection ...
Dr Reddy’s Laboratories is likely to launch its generic semaglutide injection ​in the country in March under the brand name ...
7don MSN
Dr Reddy’s says Wegovy copycat to be priced competitively, with 50–60% discounts feasible
By Rishika Sadam and Sriparna Roy HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories hopes to launch a ...
Dr Reddy's said the regulator has stated that it has now concluded its investigation into the anonymous allegations of ...
Dr. Reddy's Laboratories reports impressive financial results, with record-breaking sales and profitability in their recent quarter. The company shows strong growth in their India, North America, ...
Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent stock. Dive into the current details of Dr Reddys, including: Last ...
On Wednesday, shares of Dr Reddy's slipped 0.32 per cent to settle at Rs 1280.85, down from its previous close of Rs 1285 apiece on the BSE.
Dr. Reddy's Laboratories Ltd. closed 7.50% below its 52-week high of 1,377.95 rupees, which the company reached on June 12th.
Dr. Reddy's Laboratories Ltd. closed 8.01% short of its 52-week high of 1,377.95 rupees, which the company reached on June ...
Patent protection for semaglutide expires in India in March 2026, triggering a rush among Indian drugmakers to prepare lower-cost versions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results